Cargando…

Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial

Ketamine is an effective intervention for treatment-resistant depression (TRD), including late-in-life (LL-TRD). The proposed mechanism of antidepressant effects of ketamine is a glutamatergic surge, which can be measured by electroencephalogram (EEG) gamma oscillations. Yet, non-linear EEG biomarke...

Descripción completa

Detalles Bibliográficos
Autores principales: Murphy, Nicholas, Tamman, Amanda J. F., Lijffijt, Marijn, Amarneh, Dania, Iqbal, Sidra, Swann, Alan, Averill, Lynnette A., O’Brien, Brittany, Mathew, Sanjay J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516885/
https://www.ncbi.nlm.nih.gov/pubmed/37076582
http://dx.doi.org/10.1038/s41386-023-01586-4
_version_ 1785109218734374912
author Murphy, Nicholas
Tamman, Amanda J. F.
Lijffijt, Marijn
Amarneh, Dania
Iqbal, Sidra
Swann, Alan
Averill, Lynnette A.
O’Brien, Brittany
Mathew, Sanjay J.
author_facet Murphy, Nicholas
Tamman, Amanda J. F.
Lijffijt, Marijn
Amarneh, Dania
Iqbal, Sidra
Swann, Alan
Averill, Lynnette A.
O’Brien, Brittany
Mathew, Sanjay J.
author_sort Murphy, Nicholas
collection PubMed
description Ketamine is an effective intervention for treatment-resistant depression (TRD), including late-in-life (LL-TRD). The proposed mechanism of antidepressant effects of ketamine is a glutamatergic surge, which can be measured by electroencephalogram (EEG) gamma oscillations. Yet, non-linear EEG biomarkers of ketamine effects such as neural complexity are needed to capture broader systemic effects, represent the level of organization of synaptic communication, and elucidate mechanisms of action for treatment responders. In a secondary analysis of a randomized control trial, we investigated two EEG neural complexity markers (Lempel-Ziv complexity [LZC] and multiscale entropy [MSE]) of rapid (baseline to 240 min) and post-rapid ketamine (24 h and 7 days) effects after one 40-min infusion of IV ketamine or midazolam (active control) in 33 military veterans with LL-TRD. We also studied the relationship between complexity and Montgomery-Åsberg Depression Rating Scale score change at 7 days post-infusion. We found that LZC and MSE both increased 30 min post-infusion, with effects not localized to a single timescale for MSE. Post-rapid effects of reduced complexity with ketamine were observed for MSE. No relationship was observed between complexity and reduction in depressive symptoms. Our findings support the hypothesis that a single sub-anesthetic ketamine infusion has time-varying effects on system-wide contributions to the evoked glutamatergic surge in LL-TRD. Further, changes to complexity were observable outside the time-window previously shown for effects on gamma oscillations. These preliminary results have clinical implications in providing a functional marker of ketamine that is non-linear, amplitude-independent, and represents larger dynamic properties, providing strong advantages over linear measures in highlighting ketamine’s effects.
format Online
Article
Text
id pubmed-10516885
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-105168852023-09-24 Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial Murphy, Nicholas Tamman, Amanda J. F. Lijffijt, Marijn Amarneh, Dania Iqbal, Sidra Swann, Alan Averill, Lynnette A. O’Brien, Brittany Mathew, Sanjay J. Neuropsychopharmacology Article Ketamine is an effective intervention for treatment-resistant depression (TRD), including late-in-life (LL-TRD). The proposed mechanism of antidepressant effects of ketamine is a glutamatergic surge, which can be measured by electroencephalogram (EEG) gamma oscillations. Yet, non-linear EEG biomarkers of ketamine effects such as neural complexity are needed to capture broader systemic effects, represent the level of organization of synaptic communication, and elucidate mechanisms of action for treatment responders. In a secondary analysis of a randomized control trial, we investigated two EEG neural complexity markers (Lempel-Ziv complexity [LZC] and multiscale entropy [MSE]) of rapid (baseline to 240 min) and post-rapid ketamine (24 h and 7 days) effects after one 40-min infusion of IV ketamine or midazolam (active control) in 33 military veterans with LL-TRD. We also studied the relationship between complexity and Montgomery-Åsberg Depression Rating Scale score change at 7 days post-infusion. We found that LZC and MSE both increased 30 min post-infusion, with effects not localized to a single timescale for MSE. Post-rapid effects of reduced complexity with ketamine were observed for MSE. No relationship was observed between complexity and reduction in depressive symptoms. Our findings support the hypothesis that a single sub-anesthetic ketamine infusion has time-varying effects on system-wide contributions to the evoked glutamatergic surge in LL-TRD. Further, changes to complexity were observable outside the time-window previously shown for effects on gamma oscillations. These preliminary results have clinical implications in providing a functional marker of ketamine that is non-linear, amplitude-independent, and represents larger dynamic properties, providing strong advantages over linear measures in highlighting ketamine’s effects. Springer International Publishing 2023-04-19 2023-10 /pmc/articles/PMC10516885/ /pubmed/37076582 http://dx.doi.org/10.1038/s41386-023-01586-4 Text en © The Author(s) 2023, corrected publication 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Murphy, Nicholas
Tamman, Amanda J. F.
Lijffijt, Marijn
Amarneh, Dania
Iqbal, Sidra
Swann, Alan
Averill, Lynnette A.
O’Brien, Brittany
Mathew, Sanjay J.
Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial
title Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial
title_full Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial
title_fullStr Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial
title_full_unstemmed Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial
title_short Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial
title_sort neural complexity eeg biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516885/
https://www.ncbi.nlm.nih.gov/pubmed/37076582
http://dx.doi.org/10.1038/s41386-023-01586-4
work_keys_str_mv AT murphynicholas neuralcomplexityeegbiomarkersofrapidandpostrapidketamineeffectsinlatelifetreatmentresistantdepressionarandomizedcontroltrial
AT tammanamandajf neuralcomplexityeegbiomarkersofrapidandpostrapidketamineeffectsinlatelifetreatmentresistantdepressionarandomizedcontroltrial
AT lijffijtmarijn neuralcomplexityeegbiomarkersofrapidandpostrapidketamineeffectsinlatelifetreatmentresistantdepressionarandomizedcontroltrial
AT amarnehdania neuralcomplexityeegbiomarkersofrapidandpostrapidketamineeffectsinlatelifetreatmentresistantdepressionarandomizedcontroltrial
AT iqbalsidra neuralcomplexityeegbiomarkersofrapidandpostrapidketamineeffectsinlatelifetreatmentresistantdepressionarandomizedcontroltrial
AT swannalan neuralcomplexityeegbiomarkersofrapidandpostrapidketamineeffectsinlatelifetreatmentresistantdepressionarandomizedcontroltrial
AT averilllynnettea neuralcomplexityeegbiomarkersofrapidandpostrapidketamineeffectsinlatelifetreatmentresistantdepressionarandomizedcontroltrial
AT obrienbrittany neuralcomplexityeegbiomarkersofrapidandpostrapidketamineeffectsinlatelifetreatmentresistantdepressionarandomizedcontroltrial
AT mathewsanjayj neuralcomplexityeegbiomarkersofrapidandpostrapidketamineeffectsinlatelifetreatmentresistantdepressionarandomizedcontroltrial